Hims & Hers Health (HIMS) Cash & Equivalents (2019 - 2026)
Hims & Hers Health (HIMS) posted Cash & Equivalents of $222.3 million for Q1 2026, down 2.78% sequentially from $228.6 million in Q4 2025, and down 18.8% YoY from $273.7 million in Q1 2025.
Hims & Hers Health (HIMS) Cash & Equivalents (2019 - 2026) Analysis & Trends
Hims & Hers Health has reported Cash & Equivalents for 8 years, with the latest figure at $222.3 million in Q1 2026.
- Quarterly Cash & Equivalents fell 18.8% year-over-year to $222.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.3 million (down 18.8% YoY) and the FY2025 annual result came in at $228.6 million, up 3.64% from the prior year.
- Cash & Equivalents retreated to $222.3 million in Q1 2026 per HIMS's latest filing, from $228.6 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $1.1 billion in Q2 2025 and troughed at $46.8 million in Q4 2022.
- A 5-year average of $193.7 million and a median of $105.2 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 48.64% in 2022, then jumped 769.78% in 2025.
- Over 5 years, Cash & Equivalents stood at $46.8 million in 2022, then soared by 106.67% to $96.7 million in 2023, then soared by 128.2% to $220.6 million in 2024, then rose by 3.64% to $228.6 million in 2025, then declined by 2.78% to $222.3 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $222.3 million, $228.6 million, and $345.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Hims & Hers Health | 7.42 Bn | 6.57 Bn | 480.80 Mn | 609.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 609.81 Mn |
| Mar 31, 2026 | 222.27 Mn |
| Dec 31, 2025 | 228.62 Mn |
| Sep 30, 2025 | 345.78 Mn |
| Jun 30, 2025 | 1.12 Bn |
| Mar 31, 2025 | 273.74 Mn |
| Dec 31, 2024 | 220.58 Mn |
| Sep 30, 2024 | 165.52 Mn |
| Jun 30, 2024 | 129.30 Mn |
| Mar 31, 2024 | 105.24 Mn |
| Dec 31, 2023 | 96.66 Mn |
| Sep 30, 2023 | 58.00 Mn |
| Jun 30, 2023 | 65.42 Mn |
| Mar 31, 2023 | 48.75 Mn |
| Dec 31, 2022 | 46.77 Mn |
| Sep 30, 2022 | 57.96 Mn |
| Jun 30, 2022 | 55.03 Mn |
| Mar 31, 2022 | 48.28 Mn |
| Dec 31, 2021 | 71.78 Mn |
| Sep 30, 2021 | 64.77 Mn |